Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 28
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Biomol NMR Assign ; 17(2): 167-171, 2023 12.
Article de Anglais | MEDLINE | ID: mdl-37233945

RÉSUMÉ

Acyl carrier proteins (ACPs) are universally conserved proteins amongst different species and are involved in fatty acid synthesis. Bacteria utilize ACPs as acyl carriers and donors for the synthesis of products such as endotoxins or acyl homoserine lactones (AHLs), which are used in quorum sensing mechanisms. In this study, wehave expressed isotopically labeled holo-ACP from Burkholderia mallei in Escherichia coli to assign 100% of non-proline backbone amide (HN) resonances, 95.5% of aliphatic carbon resonances and 98.6% of aliphatic hydrogen sidechain resonances.


Sujet(s)
Protéine ACP , Burkholderia mallei , Protéine ACP/métabolisme , Burkholderia mallei/métabolisme , Résonance magnétique nucléaire biomoléculaire , Escherichia coli/métabolisme , Protéines bactériennes/métabolisme
2.
PLoS One ; 15(11): e0242593, 2020.
Article de Anglais | MEDLINE | ID: mdl-33227031

RÉSUMÉ

Bacterial efflux pumps are an important pathogenicity trait because they extrude a variety of xenobiotics. Our laboratory previously identified in silico Burkholderia collagen-like protein 8 (Bucl8) in the hazardous pathogens Burkholderia pseudomallei and Burkholderia mallei. We hypothesize that Bucl8, which contains two predicted tandem outer membrane efflux pump domains, is a component of a putative efflux pump. Unique to Bucl8, as compared to other outer membrane proteins, is the presence of an extended extracellular region containing a collagen-like (CL) domain and a non-collagenous C-terminus (Ct). Molecular modeling and circular dichroism spectroscopy with a recombinant protein, corresponding to this extracellular CL-Ct portion of Bucl8, demonstrated that it adopts a collagen triple helix, whereas functional assays screening for Bucl8 ligands identified binding to fibrinogen. Bioinformatic analysis of the bucl8 gene locus revealed it resembles a classical efflux-pump operon. The bucl8 gene is co-localized with downstream fusCDE genes encoding fusaric acid (FA) resistance, and with an upstream gene, designated as fusR, encoding a LysR-type transcriptional regulator. Using reverse transcriptase (RT)-qPCR, we defined the boundaries and transcriptional organization of the fusR-bucl8-fusCDE operon. We found exogenous FA induced bucl8 transcription over 80-fold in B. pseudomallei, while deletion of the entire bucl8 locus decreased the minimum inhibitory concentration of FA 4-fold in its isogenic mutant. We furthermore showed that the putative Bucl8-associated pump expressed in the heterologous Escherichia coli host confers FA resistance. On the contrary, the Bucl8-associated pump did not confer resistance to a panel of clinically-relevant antimicrobials in Burkholderia and E. coli. We finally demonstrated that deletion of the bucl8-locus drastically affects the growth of the mutant in L-broth. We determined that Bucl8 is a component of a novel tetrapartite efflux pump, which confers FA resistance, fibrinogen binding, and optimal growth.


Sujet(s)
Burkholderia mallei/métabolisme , Burkholderia pseudomallei/métabolisme , Protéines de transport membranaire/métabolisme , Protéines de la membrane externe bactérienne/métabolisme , Protéines de la membrane externe bactérienne/physiologie , Burkholderia/génétique , Burkholderia/métabolisme , Burkholderia mallei/génétique , Burkholderia pseudomallei/génétique , Collagène/métabolisme , Multirésistance bactérienne aux médicaments/génétique , Escherichia coli/génétique , Protéines Escherichia coli/génétique , Gènes bactériens/effets des médicaments et des substances chimiques , Opéron/effets des médicaments et des substances chimiques , Facteurs de transcription/métabolisme
3.
Vet Pathol ; 55(2): 258-267, 2018 03.
Article de Anglais | MEDLINE | ID: mdl-29145795

RÉSUMÉ

Burkholderia mallei causes the highly contagious and debilitating zoonosis glanders, which infects via inhalation or percutaneous inoculation and often culminates in life-threatening pneumonia and sepsis. In humans, glanders is difficult to diagnose and requires prolonged antibiotic therapy with low success rates. No vaccine exists to protect against B. mallei, and there is concern regarding its use as a bioweapon. The authors previously identified the protein BpaB as a potential target for devising therapies due to its role in adherence to host cells and the formation of biofilms in vitro and its contribution to pathogenicity in a mouse model of glanders. In the present study, the authors developed an immunostaining approach to probe tissues of experimentally infected animals and demonstrated that BpaB is produced exclusively in vivo by wild-type B. mallei in target organs from mice and marmosets. They detected the expression of BpaB by B. mallei both extracellularly and within macrophages, neutrophils, and epithelial cells in respiratory tissues (7/10 marmoset; 2/2 mouse). The authors also noted the intracellular expression of BpaB by B. mallei in macrophages in the regional lymph nodes of mice (2/2 tissues) and MALT of marmosets (4/5 tissues). It is interesting that B. mallei bacteria infecting distal organs did not express BpaB (2/2 mice; 3/3 marmosets), suggesting that the protein is not necessary for bacterial fitness in these anatomic locations. These findings underscore the value of BpaB as a target for developing medical countermeasures and provide insight into its role in pathogenesis.


Sujet(s)
Burkholderia mallei/pathogénicité , Morve/microbiologie , Facteurs de virulence/métabolisme , Animaux , Anticorps antibactériens/immunologie , Antigènes bactériens/immunologie , Burkholderia mallei/immunologie , Burkholderia mallei/métabolisme , Callithrix/microbiologie , Morve/métabolisme , Macrophages/microbiologie , Souris , Souris de lignée BALB C , Facteurs de virulence/immunologie
4.
Article de Anglais | MEDLINE | ID: mdl-29164069

RÉSUMÉ

Burkholderia is a genus within the ß-Proteobacteriaceae that contains at least 90 validly named species which can be found in a diverse range of environments. A number of pathogenic species occur within the genus. These include Burkholderia cenocepacia and Burkholderia multivorans, opportunistic pathogens that can infect the lungs of patients with cystic fibrosis, and are members of the Burkholderia cepacia complex (Bcc). Burkholderia pseudomallei is also an opportunistic pathogen, but in contrast to Bcc species it causes the tropical human disease melioidosis, while its close relative Burkholderia mallei is the causative agent of glanders in horses. For these pathogens to survive within a host and cause disease they must be able to acquire iron. This chemical element is essential for nearly all living organisms due to its important role in many enzymes and metabolic processes. In the mammalian host, the amount of accessible free iron is negligible due to the low solubility of the metal ion in its higher oxidation state and the tight binding of this element by host proteins such as ferritin and lactoferrin. As with other pathogenic bacteria, Burkholderia species have evolved an array of iron acquisition mechanisms with which to capture iron from the host environment. These mechanisms include the production and utilization of siderophores and the possession of a haem uptake system. Here, we summarize the known mechanisms of iron acquisition in pathogenic Burkholderia species and discuss the evidence for their importance in the context of virulence and the establishment of infection in the host. We have also carried out an extensive bioinformatic analysis to identify which siderophores are produced by each Burkholderia species that is pathogenic to humans.


Sujet(s)
Infections à Burkholderia/métabolisme , Infections à Burkholderia/microbiologie , Burkholderia/métabolisme , Burkholderia/pathogénicité , Fer/métabolisme , Virulence , Animaux , Burkholderia/classification , Burkholderia/génétique , Burkholderia gladioli/métabolisme , Burkholderia gladioli/pathogénicité , Burkholderia mallei/métabolisme , Burkholderia mallei/pathogénicité , Burkholderia pseudomallei/métabolisme , Burkholderia pseudomallei/pathogénicité , Biologie informatique , Mucoviscidose/microbiologie , Ferritines/métabolisme , Morve , Hème/métabolisme , Equus caballus , Humains , Lactoferrine/métabolisme , Poumon/microbiologie , Mélioïdose/microbiologie , Sidérophores/métabolisme
5.
Nat Commun ; 8(1): 115, 2017 07 24.
Article de Anglais | MEDLINE | ID: mdl-28740137

RÉSUMÉ

Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm), the etiologic agents of melioidosis and glanders, respectively, cause severe disease in both humans and animals. Studies have highlighted the importance of Bp and Bm lipopolysaccharides (LPS) as vaccine candidates. Here we describe the synthesis of seven oligosaccharides as the minimal structures featuring all of the reported acetylation/methylation patterns associated with Bp and Bm LPS O-antigens (OAgs). Our approach is based on the conversion of an L-rhamnose into a 6-deoxy-L-talose residue at a late stage of the synthetic sequence. Using biochemical and biophysical methods, we demonstrate the binding of several Bp and Bm LPS-specific monoclonal antibodies with terminal OAg residues. Mice immunized with terminal disaccharide-CRM197 constructs produced high-titer antibody responses that crossreacted with Bm-like OAgs. Collectively, these studies serve as foundation for the development of novel therapeutics, diagnostics, and vaccine candidates to combat diseases caused by Bp and Bm.Melioidosis and glanders are multifaceted infections caused by gram-negative bacteria. Here, the authors synthesize a series of oligosaccharides that mimic the lipopolysaccharides present on the pathogens' surface and use them to develop novel glycoconjugates for vaccine development.


Sujet(s)
Anticorps monoclonaux/immunologie , Antigènes bactériens/métabolisme , Burkholderia mallei/métabolisme , Burkholderia pseudomallei/métabolisme , Épitopes/immunologie , Lipopolysaccharides/immunologie , Animaux , Antigènes bactériens/génétique , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Vaccins antibactériens/immunologie , Burkholderia mallei/génétique , Burkholderia pseudomallei/génétique , Femelle , Régulation de l'expression des gènes bactériens/physiologie , Lipopolysaccharides/composition chimique , Lipopolysaccharides/métabolisme , Mélioïdose/prévention et contrôle , Souris , Souris de lignée BALB C
6.
Infect Immun ; 85(1)2017 Jan.
Article de Anglais | MEDLINE | ID: mdl-27799332

RÉSUMÉ

Burkholderia mallei and B. pseudomallei cause glanders and melioidosis, respectively, in humans and animals. A hallmark of pathogenesis is the formation of granulomas containing multinucleated giant cells (MNGCs) and cell death. These processes depend on type 6 secretion system 1 (T6SS-1), which is required for virulence in animals. We examined the cell biology of MNGC formation and cell death. We found that chloroquine diphosphate (CLQ), an antimalarial drug, inhibits Burkholderia growth, phagosomal escape, and subsequent MNGC formation. This depends on CLQ's ability to neutralize the acid pH because other alkalinizing compounds similarly inhibit escape and MNGC formation. CLQ inhibits bacterial virulence protein expression because T6SS-1 and some effectors of type 3 secretion system 3 (T3SS-3), which is also required for virulence, are expressed at acid pH. We show that acid pH upregulates the expression of Hcp1 of T6SS-1 and TssM, a protein coregulated with T6SS-1. Finally, we demonstrate that CLQ treatment of Burkholderia-infected Madagascar hissing cockroaches (HCs) increases their survival. This study highlights the multiple mechanisms by which CLQ inhibits growth and virulence and suggests that CLQ be further tested and considered, in conjunction with antibiotic use, for the treatment of diseases caused by Burkholderia.


Sujet(s)
Antiacides gastriques/pharmacologie , Burkholderia mallei/effets des médicaments et des substances chimiques , Burkholderia pseudomallei/effets des médicaments et des substances chimiques , Chloroquine/pharmacologie , Cellules géantes/effets des médicaments et des substances chimiques , Systèmes de sécrétion de type VI/effets des médicaments et des substances chimiques , Virulence/effets des médicaments et des substances chimiques , Animaux , Protéines bactériennes/métabolisme , Burkholderia mallei/métabolisme , Burkholderia pseudomallei/métabolisme , Lignée cellulaire , Morve/traitement médicamenteux , Morve/microbiologie , Concentration en ions d'hydrogène , Mélioïdose/traitement médicamenteux , Mélioïdose/microbiologie , Souris , Systèmes de sécrétion de type III/effets des médicaments et des substances chimiques , Facteurs de virulence/métabolisme
7.
PLoS One ; 11(9): e0163294, 2016.
Article de Anglais | MEDLINE | ID: mdl-27643499

RÉSUMÉ

Oxalic acid is produced by a variety of organisms ranging from simple microbes to complex animals. This acid has been proposed to fulfill various physiological and pathological functions which vary between organisms. In bacteria from the Burkholderia genus, oxalate secretion has been shown to be quorum sensing dependent and to support pathogenicity and cell viability. In light of the critical roles of oxalate in Burkholderia as well as other organisms, it is surprising that our understanding of how this simple dicarboxylate is biosynthesized remains incomplete. Here we report the expression, purification, and partial characterization of the first intact bacterial oxalate biosynthetic enzyme, Obc1, from B. mallei. An N-terminal His-tagged Bmobc1 was cloned into pDUET, expressed in E. coli BLR (DE3), and the recombinant enzyme purified by affinity chromatography. Oxalate biosynthetic enzyme assays coupled with HPLC analysis revealed that BmObc1 catalyzed the biosynthesis of oxalate, acetoacetate, and free CoA from oxaloacetate and a short chain acyl-CoA following Michaelis-Menten kinetics. Optimal enzyme activity was measured at pH 8.0 and a temperature around 44°C. Kinetic analysis conducted under conditions of saturating acetyl-CoA and varying oxaloacetate concentrations resulted in a calculated Km value for oxaloacetate of 94.3± 9.2 µM (mean ± SE). Under conditions of saturating oxaloacetate concentration and varying acyl-CoA (acetyl- or propionyl-CoA) concentrations kinetic analysis generated a calculated Km value of 26.8 ± 2.3 µM (mean ± SE) for acetyl-CoA and 104.4 ± 12.7 µM for propionyl-CoA. The significantly lower Km for acetyl-CoA suggests that it is strongly favored as a substrate over propionyl-CoA.


Sujet(s)
Protéines bactériennes/métabolisme , Burkholderia mallei/métabolisme , Oxalates/métabolisme , Burkholderia mallei/génétique , Gènes bactériens , Cinétique , Spécificité du substrat
8.
BMC Bioinformatics ; 17: 387, 2016 Sep 20.
Article de Anglais | MEDLINE | ID: mdl-27650316

RÉSUMÉ

BACKGROUND: Burkholderia mallei and B. pseudomallei are the causative agents of glanders and melioidosis, respectively, diseases with high morbidity and mortality rates. B. mallei and B. pseudomallei are closely related genetically; B. mallei evolved from an ancestral strain of B. pseudomallei by genome reduction and adaptation to an obligate intracellular lifestyle. Although these two bacteria cause different diseases, they share multiple virulence factors, including bacterial secretion systems, which represent key components of bacterial pathogenicity. Despite recent progress, the secretion system proteins for B. mallei and B. pseudomallei, their pathogenic mechanisms of action, and host factors are not well characterized. RESULTS: We previously developed a manually curated database, DBSecSys, of bacterial secretion system proteins for B. mallei. Here, we report an expansion of the database with corresponding information about B. pseudomallei. DBSecSys 2.0 contains comprehensive literature-based and computationally derived information about B. mallei ATCC 23344 and literature-based and computationally derived information about B. pseudomallei K96243. The database contains updated information for 163 B. mallei proteins from the previous database and 61 additional B. mallei proteins, and new information for 281 B. pseudomallei proteins associated with 5 secretion systems, their 1,633 human- and murine-interacting targets, and 2,400 host-B. mallei interactions and 2,286 host-B. pseudomallei interactions. The database also includes information about 13 pathogenic mechanisms of action for B. mallei and B. pseudomallei secretion system proteins inferred from the available literature or computationally. Additionally, DBSecSys 2.0 provides details about 82 virulence attenuation experiments for 52 B. mallei secretion system proteins and 98 virulence attenuation experiments for 61 B. pseudomallei secretion system proteins. We updated the Web interface and data access layer to speed-up users' search of detailed information for orthologous proteins related to secretion systems of the two pathogens. CONCLUSIONS: The updates of DBSecSys 2.0 provide unique capabilities to access comprehensive information about secretion systems of B. mallei and B. pseudomallei. They enable studies and comparisons of corresponding proteins of these two closely related pathogens and their host-interacting partners. The database is available at http://dbsecsys.bhsai.org .


Sujet(s)
Protéines bactériennes/métabolisme , Systèmes bactériens de sécrétion/métabolisme , Burkholderia mallei/pathogénicité , Burkholderia pseudomallei/pathogénicité , Bases de données de protéines , Animaux , Protéines bactériennes/génétique , Systèmes bactériens de sécrétion/génétique , Burkholderia mallei/génétique , Burkholderia mallei/métabolisme , Burkholderia pseudomallei/génétique , Burkholderia pseudomallei/métabolisme , Humains , Souris , Facteurs de virulence/génétique , Facteurs de virulence/métabolisme
9.
PLoS Negl Trop Dis ; 9(6): e0003863, 2015.
Article de Anglais | MEDLINE | ID: mdl-26114445

RÉSUMÉ

BACKGROUND: In this study, a Burkholderia mallei tonB mutant (TMM001) deficient in iron acquisition was constructed, characterized, and evaluated for its protective properties in acute inhalational infection models of murine glanders and melioidosis. METHODOLOGY/PRINCIPAL FINDINGS: Compared to the wild-type, TMM001 exhibits slower growth kinetics, siderophore hyper-secretion and the inability to utilize heme-containing proteins as iron sources. A series of animal challenge studies showed an inverse correlation between the percentage of survival in BALB/c mice and iron-dependent TMM001 growth. Upon evaluation of TMM001 as a potential protective strain against infection, we found 100% survival following B. mallei CSM001 challenge of mice previously receiving 1.5 x 10(4) CFU of TMM001. At 21 days post-immunization, TMM001-treated animals showed significantly higher levels of B. mallei-specific IgG1, IgG2a and IgM when compared to PBS-treated controls. At 48 h post-challenge, PBS-treated controls exhibited higher levels of serum inflammatory cytokines and more severe pathological damage to target organs compared to animals receiving TMM001. In a cross-protection study of acute inhalational melioidosis with B. pseudomallei, TMM001-treated mice were significantly protected. While wild type was cleared in all B. mallei challenge studies, mice failed to clear TMM001. CONCLUSIONS/SIGNIFICANCE: Although further work is needed to prevent chronic infection by TMM001 while maintaining immunogenicity, our attenuated strain demonstrates great potential as a backbone strain for future vaccine development against both glanders and melioidosis.


Sujet(s)
Protéines bactériennes/génétique , Vaccins antibactériens/génétique , Burkholderia mallei/génétique , Morve/prévention et contrôle , Mélioïdose/prévention et contrôle , Protéines membranaires/génétique , Animaux , Burkholderia mallei/immunologie , Burkholderia mallei/métabolisme , Clonage moléculaire , Amorces ADN/génétique , Découverte de médicament/méthodes , Femelle , Fer/métabolisme , Souris , Souris de lignée BALB C , Plasmides/génétique , Analyse de survie
10.
PLoS One ; 10(5): e0126437, 2015.
Article de Anglais | MEDLINE | ID: mdl-25993100

RÉSUMÉ

Burkholderia mallei is a highly pathogenic bacterium that causes the zoonosis glanders. Previous studies indicated that the genome of the organism contains eight genes specifying autotransporter proteins, which are important virulence factors of Gram-negative bacteria. In the present study, we report the characterization of one of these autotransporters, BpaB. Database searches identified the bpaB gene in ten B. mallei isolates and the predicted proteins were 99-100% identical. Comparative sequence analyses indicate that the gene product is a trimeric autotransporter of 1,090 amino acids with a predicted molecular weight of 105-kDa. Consistent with this finding, we discovered that recombinant bacteria expressing bpaB produce a protein of ≥ 300-kDa on their surface that is reactive with a BpaB-specific monoclonal antibody. Analysis of sera from mice infected with B. mallei indicated that animals produce antibodies against BpaB during the course of disease, thus establishing production of the autotransporter in vivo. To gain insight on its role in virulence, we inactivated the bpaB gene of B. mallei strain ATCC 23344 and determined the median lethal dose of the mutant in a mouse model of aerosol infection. These experiments revealed that the bpaB mutation attenuates virulence 8-14 fold. Using a crystal violet-based assay, we also discovered that constitutive production of BpaB on the surface of B. mallei promotes biofilm formation. To our knowledge, this is the first report of a biofilm factor for this organism.


Sujet(s)
Protéines bactériennes/génétique , Biofilms/croissance et développement , Burkholderia mallei/génétique , Burkholderia mallei/pathogénicité , Morve/microbiologie , Systèmes de sécrétion de type V/génétique , Aérosols , Animaux , Anticorps antibactériens/composition chimique , Anticorps monoclonaux/composition chimique , Protéines bactériennes/composition chimique , Protéines bactériennes/métabolisme , Burkholderia mallei/métabolisme , Lignée cellulaire , Clonage moléculaire , Cellules épithéliales/microbiologie , Cellules épithéliales/anatomopathologie , Escherichia coli/génétique , Escherichia coli/métabolisme , Femelle , Délétion de gène , Expression des gènes , Morve/mortalité , Morve/anatomopathologie , Morve/transmission , Humains , Macrophages/microbiologie , Macrophages/anatomopathologie , Souris , Souris de lignée BALB C , Protéines recombinantes/génétique , Protéines recombinantes/métabolisme , Analyse de survie , Systèmes de sécrétion de type V/composition chimique , Systèmes de sécrétion de type V/métabolisme , Virulence
11.
Exp Biol Med (Maywood) ; 240(6): 742-51, 2015 Jun.
Article de Anglais | MEDLINE | ID: mdl-25908634

RÉSUMÉ

Melioidosis is an emerging, potentially fatal disease caused by Burkholderia pseudomallei, which requires prolonged antibiotic treatment to prevent disease relapse. However, difficulties in laboratory diagnosis of melioidosis may delay treatment and affect disease outcomes. Isolation of B. pseudomallei from clinical specimens has been improved with the use of selective media. However, even with positive cultures, identification of B. pseudomallei can be difficult in clinical microbiology laboratories, especially in non-endemic areas where clinical suspicion is low. Commercial identification systems may fail to distinguish between B. pseudomallei and closely related species such as Burkholderia thailandensis. Genotypic identification of suspected isolates can be achieved by sequencing of gene targets such as groEL which offer higher discriminative power than 16S rRNA. Specific PCR-based identification of B. pseudomallei has also been developed using B. pseudomallei-specific gene targets such as Type III secretion system and Tat-domain protein. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolutionary technique for pathogen identification, has been shown to be potentially useful for rapid identification of B. pseudomallei, although existing databases require optimization by adding reference spectra for B. pseudomallei. Despite these advances in bacterial identification, diagnostic problems encountered in culture-negative cases remain largely unresolved. Although various serological tests have been developed, they are generally unstandardized "in house" assays and have low sensitivities and specificities. Although specific PCR assays have been applied to direct clinical and environmental specimens, the sensitivities for diagnosis remain to be evaluated. Metabolomics is an uprising tool for studying infectious diseases and may offer a novel approach for exploring potential diagnostic biomarkers. The metabolomics profiles of B. pseudomallei culture supernatants can be potentially distinguished from those of related bacterial species including B. thailandensis . Further studies using bacterial cultures and direct patient samples are required to evaluate the potential of metabolomics for improving diagnosis of melioidosis.


Sujet(s)
Burkholderia mallei/génétique , Burkholderia mallei/métabolisme , Techniques de génotypage , Mélioïdose/diagnostic , Mélioïdose/génétique , Mélioïdose/métabolisme , Métabolomique , Animaux , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Systèmes bactériens de sécrétion/génétique , Burkholderia mallei/pathogénicité , Chaperonine-60/génétique , Chaperonine-60/métabolisme , Bases de données factuelles , Techniques de génotypage/méthodes , Techniques de génotypage/tendances , Humains , Mélioïdose/microbiologie , Métabolomique/méthodes , Métabolomique/tendances , ARN bactérien/génétique , ARN bactérien/métabolisme , ARN ribosomique 16S/génétique , ARN ribosomique 16S/métabolisme
12.
Biochemistry ; 53(39): 6231-42, 2014 Oct 07.
Article de Anglais | MEDLINE | ID: mdl-25215658

RÉSUMÉ

The acyl-homoserine lactone (AHL) autoinducer mediated quorum sensing regulates virulence in several pathogenic bacteria. The hallmark of an efficient quorum sensing system relies on the tight specificity in the signal generated by each bacterium. Since AHL signal specificity is derived from the acyl-chain of the acyl-ACP (ACP = acyl carrier protein) substrate, AHL synthase enzymes must recognize and react with the native acyl-ACP with high catalytic efficiency while keeping reaction rates with non-native acyl-ACPs low. The mechanism of acyl-ACP substrate recognition in these enzymes, however, remains elusive. In this study, we investigated differences in catalytic efficiencies for shorter and longer chain acyl-ACP substrates reacting with an octanoyl-homoserine lactone synthase Burkholderia mallei BmaI1. With the exception of two-carbon shorter hexanoyl-ACP, the catalytic efficiencies of butyryl-ACP, decanoyl-ACP, and octanoyl-CoA reacting with BmaI1 decreased by greater than 20-fold compared to the native octanoyl-ACP substrate. Furthermore, we also noticed kinetic cooperativity when BmaI1 reacted with non-native acyl-donor substrates. Our kinetic data suggest that non-native acyl-ACP substrates are unable to form a stable and productive BmaI1·acyl-ACP·SAM ternary complex and are thus effectively discriminated by the enzyme. These results offer insights into the molecular basis of substrate recognition for the BmaI1 enzyme.


Sujet(s)
Protéine ACP/métabolisme , Acyl-butyrolactones/métabolisme , Protéines bactériennes/métabolisme , Ligases/métabolisme , Protéines bactériennes/génétique , Biocatalyse , Burkholderia mallei/enzymologie , Burkholderia mallei/génétique , Burkholderia mallei/métabolisme , Chromatographie en phase liquide à haute performance , Cinétique , Ligases/génétique , Spécificité du substrat
13.
Microbiologyopen ; 3(5): 610-29, 2014 Oct.
Article de Anglais | MEDLINE | ID: mdl-25044501

RÉSUMÉ

Here, we constructed stable, chromosomal, constitutively expressed, green and red fluorescent protein (GFP and RFP) as reporters in the select agents, Bacillus anthracis, Yersinia pestis, Burkholderia mallei, and Burkholderia pseudomallei. Using bioinformatic approaches and other experimental analyses, we identified P0253 and P1 as potent promoters that drive the optimal expression of fluorescent reporters in single copy in B. anthracis and Burkholderia spp. as well as their surrogate strains, respectively. In comparison, Y. pestis and its surrogate strain need two chromosomal copies of cysZK promoter (P2cysZK) for optimal fluorescence. The P0253-, P2cysZK-, and P1-driven GFP and RFP fusions were first cloned into the vectors pRP1028, pUC18R6KT-mini-Tn7T-Km, pmini-Tn7-gat, or their derivatives. The resultant constructs were delivered into the respective surrogates and subsequently into the select agent strains. The chromosomal GFP- and RFP-tagged strains exhibited bright fluorescence at an exposure time of less than 200 msec and displayed the same virulence traits as their wild-type parental strains. The utility of the tagged strains was proven by the macrophage infection assays and lactate dehydrogenase release analysis. Such strains will be extremely useful in high-throughput screens for novel compounds that could either kill these organisms, or interfere with critical virulence processes in these important bioweapon agents and during infection of alveolar macrophages.


Sujet(s)
Bacillus anthracis/génétique , Burkholderia mallei/génétique , Burkholderia pseudomallei/génétique , Chromosomes de bactérie/génétique , Protéines à fluorescence verte/génétique , Protéines luminescentes/génétique , Yersinia pestis/génétique , Bacillus anthracis/métabolisme , Bacillus anthracis/pathogénicité , Infections bactériennes/microbiologie , Burkholderia mallei/métabolisme , Burkholderia mallei/pathogénicité , Burkholderia pseudomallei/métabolisme , Burkholderia pseudomallei/pathogénicité , Lignée cellulaire , Chromosomes de bactérie/métabolisme , Expression des gènes , Gènes rapporteurs , Protéines à fluorescence verte/métabolisme , Humains , Protéines luminescentes/métabolisme , Macrophages alvéolaires/microbiologie , Virulence , Yersinia pestis/métabolisme , Yersinia pestis/pathogénicité ,
14.
BMC Bioinformatics ; 15: 244, 2014 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-25030112

RÉSUMÉ

BACKGROUND: Bacterial pathogenicity represents a major public health concern worldwide. Secretion systems are a key component of bacterial pathogenicity, as they provide the means for bacterial proteins to penetrate host-cell membranes and insert themselves directly into the host cells' cytosol. Burkholderia mallei is a Gram-negative bacterium that uses multiple secretion systems during its host infection life cycle. To date, the identities of secretion system proteins for B. mallei are not well known, and their pathogenic mechanisms of action and host factors are largely uncharacterized. DESCRIPTION: We present the Database of Burkholderia malleiSecretion Systems (DBSecSys), a compilation of manually curated and computationally predicted bacterial secretion system proteins and their host factors. Currently, DBSecSys contains comprehensive experimentally and computationally derived information about B. mallei strain ATCC 23344. The database includes 143 B. mallei proteins associated with five secretion systems, their 1,635 human and murine interacting targets, and the corresponding 2,400 host-B. mallei interactions. The database also includes information about 10 pathogenic mechanisms of action for B. mallei secretion system proteins inferred from the available literature. Additionally, DBSecSys provides details about 42 virulence attenuation experiments for 27 B. mallei secretion system proteins. Users interact with DBSecSys through a Web interface that allows for data browsing, querying, visualizing, and downloading. CONCLUSIONS: DBSecSys provides a comprehensive, systematically organized resource of experimental and computational data associated with B. mallei secretion systems. It provides the unique ability to study secretion systems not only through characterization of their corresponding pathogen proteins, but also through characterization of their host-interacting partners.The database is available at https://applications.bhsai.org/dbsecsys.


Sujet(s)
Protéines bactériennes/métabolisme , Systèmes bactériens de sécrétion , Burkholderia mallei/physiologie , Bases de données de protéines , Animaux , Burkholderia mallei/métabolisme , Burkholderia mallei/pathogénicité , Interactions hôte-pathogène , Humains , Souris , Facteurs de virulence/métabolisme
15.
Mol Cell Proteomics ; 12(11): 3036-51, 2013 Nov.
Article de Anglais | MEDLINE | ID: mdl-23800426

RÉSUMÉ

Burkholderia mallei is an infectious intracellular pathogen whose virulence and resistance to antibiotics makes it a potential bioterrorism agent. Given its genetic origin as a commensal soil organism, it is equipped with an extensive and varied set of adapted mechanisms to cope with and modulate host-cell environments. One essential virulence mechanism constitutes the specialized secretion systems that are designed to penetrate host-cell membranes and insert pathogen proteins directly into the host cell's cytosol. However, the secretion systems' proteins and, in particular, their host targets are largely uncharacterized. Here, we used a combined in silico, in vitro, and in vivo approach to identify B. mallei proteins required for pathogenicity. We used bioinformatics tools, including orthology detection and ab initio predictions of secretion system proteins, as well as published experimental Burkholderia data to initially select a small number of proteins as putative virulence factors. We then used yeast two-hybrid assays against normalized whole human and whole murine proteome libraries to detect and identify interactions among each of these bacterial proteins and host proteins. Analysis of such interactions provided both verification of known virulence factors and identification of three new putative virulence proteins. We successfully created insertion mutants for each of these three proteins using the virulent B. mallei ATCC 23344 strain. We exposed BALB/c mice to mutant strains and the wild-type strain in an aerosol challenge model using lethal B. mallei doses. In each set of experiments, mice exposed to mutant strains survived for the 21-day duration of the experiment, whereas mice exposed to the wild-type strain rapidly died. Given their in vivo role in pathogenicity, and based on the yeast two-hybrid interaction data, these results point to the importance of these pathogen proteins in modulating host ubiquitination pathways, phagosomal escape, and actin-cytoskeleton rearrangement processes.


Sujet(s)
Burkholderia mallei/métabolisme , Burkholderia mallei/pathogénicité , Interactions hôte-pathogène/physiologie , Facteurs de virulence/métabolisme , Animaux , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme , Burkholderia mallei/génétique , Femelle , Interactions hôte-pathogène/génétique , Humains , Souris , Souris de lignée BALB C , Mutagenèse par insertion , Cartographie d'interactions entre protéines , Protéomique , Techniques de double hybride , Virulence/génétique , Virulence/physiologie , Facteurs de virulence/génétique
16.
Article de Russe | MEDLINE | ID: mdl-23805644

RÉSUMÉ

AIM: Comparative characteristic of diagnostic value of main cultural-biological characteristics of Burkholderiae pseudomallei group. MATERIALS AND METHODS: 59 strains of B. pseudomallei, 14 --B. mallei and 5--B. thailandensis were used in the study. Biochemical characteristics were studied by generally accepted methods, antigenic properties were evaluated in agglutination reaction and immunoelectrophoresis, virulence was determined by Dlm for laboratory animals, antibiotic sensitivity was verified by disc-diffusion method. RESULTS: Passaging of B. pseudomallei and B. mallei in mice results in increase of virulence, preservation of initial sensitivity to antibiotics, contraction of precipitogen specter. During therapy of experimental melioidosis in guinea pigs resistance to chemopreparations of various groups is formed. Varying degree of virulence and sensitivity to antibiotics of various B. thailandensis strains was established. Dependence of sensitivity on in vitro cultivation was not detected. CONCLUSION: Stability of diagnostically significant tests used for identification of Burkholderiae pseudomallei group was established. Relevance of attribute set expansion that facilitates their differentiation is justified.


Sujet(s)
Burkholderia mallei , Burkholderia pseudomallei/métabolisme , Résistance bactérienne aux médicaments/physiologie , Mélioïdose/traitement médicamenteux , Animaux , Burkholderia mallei/métabolisme , Burkholderia mallei/pathogénicité , Burkholderia pseudomallei/pathogénicité , Modèles animaux de maladie humaine , Tests d'agents antimicrobiens par diffusion à partir de disques , Cochons d'Inde , Mélioïdose/métabolisme , Mélioïdose/microbiologie , Souris
17.
BMC Vet Res ; 8: 154, 2012 Sep 02.
Article de Anglais | MEDLINE | ID: mdl-22937975

RÉSUMÉ

BACKGROUND: The allergic test of mallein is one of the most frequently used tests, together with the Complement Fixation Test (CFT), for the diagnosis of glanders in endemic areas. Mallein, a purified protein derivative (PPD), is produced similarly to PPD tuberculin and the end product is a primarily proteic antigen, which is only poorly purified. The immuno-allergic activity of mallein is believed to be due to a high molecular weight group of proteins present in the antigen. To improve the quality of the antigen, in terms of sensitivity and specificity, a new method of mallein production was developed, in which purification was accomplished by ultrafiltration in a Tangential Flow Filtration system (TFF). RESULTS: The TFF methodology efficiently separated the high and low molecular weight protein groups of mallein. The five TFF-purified malleins, produced from Burkholderia mallei strains isolated from clinical cases of glanders in Brazil, proved to be more potent than standard mallein in the induction of an allergic reaction in sensitized animals. Regarding specificity, two of the purified malleins were equivalent to the standard and three were less specific. CONCLUSION: Some of the TFF-purified malleins showed considerable potential to be used as an auxiliary test in the diagnosis of glanders.


Sujet(s)
Antigènes bactériens/immunologie , Morve/diagnostic , Tests immunologiques/médecine vétérinaire , Animaux , Anticorps antibactériens/sang , Burkholderia mallei/classification , Burkholderia mallei/métabolisme , Tests de fixation du complément/médecine vétérinaire , Cochons d'Inde , Equus caballus , Reproductibilité des résultats , Sensibilité et spécificité
18.
Faraday Discuss ; 149: 23-36; discussion 63-77, 2011.
Article de Anglais | MEDLINE | ID: mdl-21413172

RÉSUMÉ

Rapid detection of the category B biothreat agents Burkholderia pseudomallei and Burkholderia mallei in acute infections is critical to ensure that appropriate treatment is administered quickly to reduce an otherwise high probability of mortality (ca. 40% for B. pseudomallei). We are developing assays that can be used in clinical laboratories or security applications for the direct detection of surface-localized and secreted macromolecules produced by these organisms. We present our current medium-throughout approach for target selection and production of Burkholderia macromolecules and describe the generation of a Fab molecule targeted to the B. mallei BimA protein. We also present development of prototype assays for detecting Burkholderia species using anti-lipopolysaccharide antibodies.


Sujet(s)
Burkholderia mallei/isolement et purification , Burkholderia pseudomallei/isolement et purification , Test ELISA/méthodes , Morve/microbiologie , Mélioïdose/microbiologie , Animaux , Burkholderia mallei/métabolisme , Burkholderia pseudomallei/métabolisme , Chaperonine-60/composition chimique , Chaperonine-60/métabolisme , Morve/diagnostic , Humains , Mélioïdose/diagnostic , Protéines des microfilaments/composition chimique , Protéines des microfilaments/métabolisme
19.
Microbiol Res ; 166(7): 531-8, 2011 Oct 20.
Article de Anglais | MEDLINE | ID: mdl-21242070

RÉSUMÉ

Although it is known that oxalic acid provides a selective advantage to the secreting microbe our understanding of how this acid is biosynthesized remains incomplete. This study reports the identification, cloning, and partial characterization of the oxalic acid biosynthetic enzyme from the animal bacterial pathogen, Burkholderia mallei. The discovered gene was named oxalate biosynthetic component (obc)1. Complementation of Burkholderia oxalate defective (Bod)1, a Burkholderia glumae mutant that lacks expression of a functional oxalic acid biosynthetic operon, revealed that the obc1 was able to rescue the no oxalate mutant phenotype. This single gene rescue is in contrast to the situation found in B. glumae which required the expression of two genes, obcA and obcB, to achieve complementation. Enzyme assays showed that even though the two Burkholderia species differed in the number of genes required to encode a functional enzyme, both catalyzed the same acyl-CoA dependent biosynthetic reaction. In addition, mutagenesis studies suggested a similar domain structure of the assembled oxalate biosynthetic enzymes whether encoded by one or two genes.


Sujet(s)
Voies de biosynthèse/génétique , Burkholderia mallei/génétique , Burkholderia mallei/métabolisme , Acide oxalique/métabolisme , Séquence d'acides aminés , Délétion de gène , Test de complémentation , Données de séquences moléculaires , Structure tertiaire des protéines , Similitude de séquences d'acides aminés
20.
J Pept Sci ; 15(9): 595-600, 2009 Sep.
Article de Anglais | MEDLINE | ID: mdl-19466693

RÉSUMÉ

Antimicrobial peptides (AMPs) are secreted in the airway and contribute to initial defence against inhaled pathogens. Infections of the respiratory tract are a major cause of morbidity and mortality in preterm newborns and in patients with cystic fibrosis (CF). In this latter group, the state of chronic lung infection is due to the ability of bacteria to grow as mucoid biofilm, a condition characterised by overproduction and release of polysaccharides (PSs). In this study, we investigate the effect of PSs produced by lung pathogens such as Pseudomonas aeruginosa, Klebsiella pneumoniae and members of the Burkholderia cepacia complex on the antibacterial activity of structurally different peptides. The AMPs tested in this study include the cathelicidin LL-37 and the beta-defensin hBD-3 from humans, both released at the alveolar level, as well as peptides from other mammals, i.e. SMAP-29, PG-1 and Bac7(1-35). Susceptibility assays, time killing and membrane permeabilization kinetics experiments were carried out to establish whether PSs produced by lung pathogens may be involved in the poor defence reaction of infected lungs and thus explain infection persistence. All the PSs investigated inhibited, albeit to a different extent, the antibacterial activity of the peptides tested, suggesting that their presence in the lungs of patients with CF may contribute to the decreased defence response of this district upon infection by PS-producing microorganisms. The results also show that inhibition of the antibacterial activity is not simply due to ionic interaction between the negatively charged PSs and the cationic AMPs, but it also involves other structural features of both interactors.


Sujet(s)
Peptides antimicrobiens cationiques/pharmacologie , Bactéries/effets des médicaments et des substances chimiques , Maladies pulmonaires/microbiologie , Polyosides bactériens/pharmacologie , Peptides antimicrobiens cationiques/synthèse chimique , Peptides antimicrobiens cationiques/composition chimique , Infections bactériennes/microbiologie , Burkholderia mallei/effets des médicaments et des substances chimiques , Burkholderia mallei/métabolisme , Cathélicidines/synthèse chimique , Cathélicidines/composition chimique , Cathélicidines/pharmacologie , Membrane cellulaire/effets des médicaments et des substances chimiques , Mucoviscidose/microbiologie , Interactions médicamenteuses , Escherichia coli/effets des médicaments et des substances chimiques , Escherichia coli/métabolisme , Humains , Cinétique , Klebsiella pneumoniae/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/métabolisme , Tests de sensibilité microbienne , Pseudomonas aeruginosa/effets des médicaments et des substances chimiques , Pseudomonas aeruginosa/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE